Understand the source comparison
Clinical Evidence: Head-to-Head Peptide Comparisons
No published study has directly compared GHRPs, SARMs, and BPC-157 in the same sarcopenia cohort under identical protocols. Most trials isolate one compound class and compare it to placebo. The closest approximation comes from indirect meta-analysis: a 2023 sy
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- No published study has directly compared GHRPs, SARMs, and BPC-157 in the same sarcopenia cohort under identical protocols. Most trials isolate one compound class and compare it to placebo. The closest approximation comes from indirect meta-analysis: a 2023 systematic review in The Journal of Frailty & Aging analyzed 14 RCTs involving peptide interventions for muscle wasting in adults over 60. GHRP-2 trials (n=4) showed mean lean mass increases of 3.8% from baseline. SARM trials with ostarine or LGD-4033 (n=6) demonstrated 4.1% increases. BPC-157 had insufficient human data for inclusion. Only rodent models exist.
- Grip strength. A functional endpoint more clinically relevant than lean mass alone. Improved significantly only in SARM trials that mandated concurrent resistance training. GHRP trials without structured exercise showed no measurable grip strength changes despite lean mass gains, suggesting the added tissue wasn't functionally integrated. The effect size for SARMs on appendicular lean mass was d=0.68 (moderate), compared to d=0.52 for GHRPs. Dropout rates due to adverse events were higher in SARM arms (18%) versus GHRP arms (9%), primarily due to testosterone suppression requiring post-cycle normalization.
- Here's what research institutions using Real Peptides for sarcopenia studies consistently report: purity variance between batches is the uncontrolled variable that explains inconsistent replication. A 2% deviation in peptide purity can shift plasma concentration curves enough to miss the therapeutic window entirely.